Eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1) expression in glioblastoma is driven by ETS1- and MYBL2-dependent transcriptional activation.
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
28 Feb 2022
28 Feb 2022
Historique:
received:
30
11
2021
accepted:
10
02
2022
revised:
04
02
2022
entrez:
1
3
2022
pubmed:
2
3
2022
medline:
2
3
2022
Statut:
epublish
Résumé
Eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1) encodes the 4EBP1 protein, a negative regulator of mRNA translation and a substrate of the mechanistic target of rapamycin (mTOR), whose function and relevance in cancer is still under debate. Here, we analyzed EIF4EBP1 expression in different glioma patient cohorts and investigated its mode of transcriptional regulation in glioblastoma cells. We verified that EIF4EBP1 mRNA is overexpressed in malignant gliomas, including isocitrate dehydrogenase (IDH)-wildtype glioblastomas, relative to non-neoplastic brain tissue in multiple publically available datasets. Our analyses revealed that EIF4EBP1 overexpression in malignant gliomas is neither due to gene amplification nor to altered DNA methylation, but rather results from aberrant transcriptional activation by distinct transcription factors. We found seven transcription factor candidates co-expressed with EIF4EBP1 in gliomas and bound to the EIF4EBP1 promoter, as revealed by chromatin immunoprecipitation (ChIP)-sequencing data. We investigated the ability of these candidates to activate the EIF4EBP1 promoter using luciferase reporter assays, which supported four transcription factors as candidate EIF4EBP1 regulators, namely MYBL2, ETS1, HIF-1A, and E2F6. Finally, by employing transient knock-down experiments to repress either of these transcription factors, we identified MYBL2 and ETS1 as the relevant transcriptional drivers of enhanced EIF4EBP1 expression in malignant glioma cells. Taken together, our findings confirm enhanced expression of EIF4EBP1 in malignant gliomas relative to non-neoplastic brain tissue and characterize the underlying molecular pathomechanisms.
Identifiants
pubmed: 35228525
doi: 10.1038/s41420-022-00883-z
pii: 10.1038/s41420-022-00883-z
pmc: PMC8885828
doi:
Types de publication
Journal Article
Langues
eng
Pagination
91Informations de copyright
© 2022. The Author(s).
Références
Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960–76.
pubmed: 28283069
pmcid: 5394987
doi: 10.1016/j.cell.2017.02.004
Haghighat A, Mader S, Pause A, Sonenberg N. Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J. 1995;14:5701–9.
pubmed: 8521827
pmcid: 394685
doi: 10.1002/j.1460-2075.1995.tb00257.x
Wang Z, Feng X, Molinolo AA, Martin D, Vitale-Cross L, Nohata N, et al. 4E-BP1 is a tumor suppressor protein reactivated by mTOR inhibition in head and neck cancer. Cancer Res. 2019;79:1438–50.
pubmed: 30894372
pmcid: 6445709
doi: 10.1158/0008-5472.CAN-18-1220
Ding M, Van der Kwast TH, Vellanki RN, Foltz WD, McKee TD, Sonenberg N, et al. The mTOR targets 4E-BP1/2 restrain tumor growth and promote hypoxia tolerance in PTEN-driven prostate cancer. Mol Cancer Res. 2018;16:682–95.
pubmed: 29453322
doi: 10.1158/1541-7786.MCR-17-0696
Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science. 2010;328:1172–6.
pubmed: 20508131
pmcid: 2893390
doi: 10.1126/science.1187532
Morita M, Gravel SP, Chenard V, Sikstrom K, Zheng L, Alain T, et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab. 2013;18:698–711.
pubmed: 24206664
doi: 10.1016/j.cmet.2013.10.001
Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H, et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell. 2007;28:501–12.
pubmed: 17996713
doi: 10.1016/j.molcel.2007.10.019
Dubois L, Magagnin MG, Cleven AH, Weppler SA, Grenacher B, Landuyt W, et al. Inhibition of 4E-BP1 sensitizes U87 glioblastoma xenograft tumors to irradiation by decreasing hypoxia tolerance. Int J Radiat Oncol Biol Phys. 2009;73:1219–27.
pubmed: 19251093
doi: 10.1016/j.ijrobp.2008.12.003
Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS, McNulty AM, et al. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Res. 2009;69:3866–73.
pubmed: 19383915
doi: 10.1158/0008-5472.CAN-08-3472
Karlsson E, Waltersson MA, Bostner J, Perez-Tenorio G, Olsson B, Hallbeck AL, et al. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1. Genes Chromosomes Cancer. 2011;50:775–87.
pubmed: 21748818
doi: 10.1002/gcc.20900
Rutkovsky AC, Yeh ES, Guest ST, Findlay VJ, Muise-Helmericks RC, Armeson K, et al. Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer. BMC Cancer. 2019;19:491.
pubmed: 31122207
pmcid: 6533768
doi: 10.1186/s12885-019-5667-4
Wu S, Wagner G. Deep computational analysis details dysregulation of eukaryotic translation initiation complex eIF4F in human cancers. Cell Syst. 2021;12:907.e6–23.e6.
Chao MW, Wang LT, Lai CY, Yang XM, Cheng YW, Lee KH, et al. eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer. Oncotarget. 2015;6:24092–104.
pubmed: 26204490
pmcid: 4695172
doi: 10.18632/oncotarget.4483
Cha YL, Li PD, Yuan LJ, Zhang MY, Zhang YJ, Rao HL, et al. EIF4EBP1 overexpression is associated with poor survival and disease progression in patients with hepatocellular carcinoma. PLoS ONE 2015;10:e0117493.
pubmed: 25658620
pmcid: 4319970
doi: 10.1371/journal.pone.0117493
Tameire F, Verginadis II, Leli NM, Polte C, Conn CS, Ojha R, et al. ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression. Nat Cell Biol. 2019;21:889–99.
pubmed: 31263264
pmcid: 6608727
doi: 10.1038/s41556-019-0347-9
Liu Y, Horn JL, Banda K, Goodman AZ, Lim Y, Jana S, et al. The androgen receptor regulates a druggable translational regulon in advanced prostate cancer. Sci Transl Med. 2019;11:eaaw4993.
pubmed: 31366581
pmcid: 6746573
doi: 10.1126/scitranslmed.aaw4993
Juliana CA, Yang J, Rozo AV, Good A, Groff DN, Wang SZ, et al. ATF5 regulates beta-cell survival during stress. Proc Natl Acad Sci USA. 2017;114:1341–6.
pubmed: 28115692
pmcid: 5307469
doi: 10.1073/pnas.1620705114
Azar R, Lasfargues C, Bousquet C, Pyronnet S. Contribution of HIF-1alpha in 4E-BP1 gene expression. Mol Cancer Res. 2013;11:54–61.
pubmed: 23175522
doi: 10.1158/1541-7786.MCR-12-0095
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803–20.
pubmed: 27157931
doi: 10.1007/s00401-016-1545-1
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231–51.
pubmed: 34185076
doi: 10.1093/neuonc/noab106
Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007;21:2683–710.
pubmed: 17974913
doi: 10.1101/gad.1596707
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
pubmed: 15758009
doi: 10.1056/NEJMoa043330
Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18:170–86.
pubmed: 33293629
doi: 10.1038/s41571-020-00447-z
Agnihotri S, Burrell KE, Wolf A, Jalali S, Hawkins C, Rutka JT, et al. Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp. 2013;61:25–41.
doi: 10.1007/s00005-012-0203-0
Bai H, Harmanci AS, Erson-Omay EZ, Li J, Coskun S, Simon M, et al. Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nat Genet. 2016;48:59–66.
pubmed: 26618343
doi: 10.1038/ng.3457
Gusev Y, Bhuvaneshwar K, Song L, Zenklusen JC, Fine H, Madhavan S. The REMBRANDT study, a large collection of genomic data from brain cancer patients. Sci Data. 2018;5:180158.
pubmed: 30106394
pmcid: 6091243
doi: 10.1038/sdata.2018.158
Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 2006;9:287–300.
pubmed: 16616334
doi: 10.1016/j.ccr.2006.03.003
Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009;69:9065–72.
pubmed: 19920198
doi: 10.1158/0008-5472.CAN-09-2307
Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, et al. Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26:3015–24.
pubmed: 18565887
doi: 10.1200/JCO.2007.15.7164
Gulluoglu S, Tuysuz EC, Sahin M, Kuskucu A, Kaan Yaltirik C, Ture U, et al. Simultaneous miRNA and mRNA transcriptome profiling of glioblastoma samples reveals a novel set of OncomiR candidates and their target genes. Brain Res. 2018;1700:199–210.
pubmed: 30176243
doi: 10.1016/j.brainres.2018.08.035
Griesinger AM, Birks DK, Donson AM, Amani V, Hoffman LM, Waziri A, et al. Characterization of distinct immunophenotypes across pediatric brain tumor types. J Immunol. 2013;191:4880–8.
pubmed: 24078694
doi: 10.4049/jimmunol.1301966
Cancer Genome Atlas Research N, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45:1113–20.
doi: 10.1038/ng.2764
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.
pubmed: 22588877
doi: 10.1158/2159-8290.CD-12-0095
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:1.
doi: 10.1126/scisignal.2004088
Court F, Le Boiteux E, Fogli A, Muller-Barthelemy M, Vaurs-Barriere C, Chautard E, et al. Transcriptional alterations in glioma result primarily from DNA methylation-independent mechanisms. Genome Res. 2019;29:1605–21.
pubmed: 31533980
pmcid: 6771409
doi: 10.1101/gr.249219.119
Kawaguchi A, Yajima N, Tsuchiya N, Homma J, Sano M, Natsumeda M, et al. Gene expression signature-based prognostic risk score in patients with glioblastoma. Cancer Sci. 2013;104:1205–10.
pubmed: 23745793
pmcid: 7657127
doi: 10.1111/cas.12214
Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004;64:6503–10.
pubmed: 15374961
doi: 10.1158/0008-5472.CAN-04-0452
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98–W102.
pubmed: 28407145
pmcid: 5570223
doi: 10.1093/nar/gkx247
GT Consortium. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45:580–5.
doi: 10.1038/ng.2653
Liao P, Han S, Qu H. Expression, prognosis, and immune infiltrates analyses of E2Fs in human brain and CNS cancer. Biomed Res Int. 2020;2020:6281635.
pubmed: 33381564
pmcid: 7755476
doi: 10.1155/2020/6281635
Davis CA, Hitz BC, Sloan CA, Chan ET, Davidson JM, Gabdank I, et al. The Encyclopedia of DNA elements (ENCODE): data portal update. Nucleic Acids Res. 2018;46:D794–801.
pubmed: 29126249
doi: 10.1093/nar/gkx1081
Consortium EP. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57–74.
doi: 10.1038/nature11247
Mimura I, Nangaku M, Kanki Y, Tsutsumi S, Inoue T, Kohro T, et al. Dynamic change of chromatin conformation in response to hypoxia enhances the expression of GLUT3 (SLC2A3) by cooperative interaction of hypoxia-inducible factor 1 and KDM3A. Mol Cell Biol. 2012;32:3018–32.
pubmed: 22645302
pmcid: 3434521
doi: 10.1128/MCB.06643-11
Musa J, Cidre-Aranaz F, Aynaud MM, Orth MF, Knott MML, Mirabeau O, et al. Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes. Nat Commun. 2019;10:4128.
pubmed: 31511524
pmcid: 6739408
doi: 10.1038/s41467-019-12071-2
Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, et al. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther. 2012;11:1488–99.
pubmed: 22564725
doi: 10.1158/1535-7163.MCT-11-0963
Lu TP, Tsai MH, Lee JM, Hsu CP, Chen PC, Lin CW, et al. Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women. Cancer Epidemiol Biomark Prev. 2010;19:2590–7.
doi: 10.1158/1055-9965.EPI-10-0332
Musa J, Orth MF, Dallmayer M, Baldauf M, Pardo C, Rotblat B, et al. Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis. Oncogene. 2016;35:4675–88.
pubmed: 26829052
doi: 10.1038/onc.2015.515
Kumar S, Sharife H, Kreisel T, Mogilevsky M, Bar-Lev L, Grunewald M, et al. Intra-tumoral metabolic zonation and resultant phenotypic diversification are dictated by blood vessel proximity. Cell Metab. 2019;30:201.e6–11.e6.
doi: 10.1016/j.cmet.2019.04.003
Voutsadakis IA. 8p11.23 Amplification in breast cancer: molecular characteristics, prognosis and targeted therapy. J Clin Med. 2020;9:3079.
Zhang X, Lv QL, Huang YT, Zhang LH, Zhou HH. Akt/FoxM1 signaling pathway-mediated upregulation of MYBL2 promotes progression of human glioma. J Exp Clin Cancer Res. 2017;36:105.
pubmed: 28784180
pmcid: 5547476
doi: 10.1186/s13046-017-0573-6
Zhang P, Pei C, Wang X, Xiang J, Sun BF, Cheng Y, et al. A balance of Yki/Sd activator and E2F1/Sd repressor complexes controls cell survival and affects organ size. Dev Cell. 2017;43:603–17. e5.
pubmed: 29207260
pmcid: 5722641
doi: 10.1016/j.devcel.2017.10.033
Li M, Ge Q, Wang W, Wang J, Lu Z. c-Jun binding site identification in K562 cells. J Genet Genomics. 2011;38:235–42.
pubmed: 21703547
doi: 10.1016/j.jgg.2011.05.004
Dittmer J. The role of the transcription factor Ets1 in carcinoma. Semin Cancer Biol. 2015;35:20–38.
pubmed: 26392377
doi: 10.1016/j.semcancer.2015.09.010
Ren F, Wang L, Shen X, Xiao X, Liu Z, Wei P, et al. MYBL2 is an independent prognostic marker that has tumor-promoting functions in colorectal cancer. Am J Cancer Res. 2015;5:1542–52.
pubmed: 26101717
pmcid: 4473330
Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC, Perou CM. In vitro and in vivo analysis of B-Myb in basal-like breast cancer. Oncogene. 2009;28:742–51.
pubmed: 19043454
doi: 10.1038/onc.2008.430
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–77.
pubmed: 24120142
pmcid: 3910500
doi: 10.1016/j.cell.2013.09.034
Hanada N, Lo HW, Day CP, Pan Y, Nakajima Y, Hung MC. Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol Carcinog. 2006;45:10–7.
pubmed: 16299810
doi: 10.1002/mc.20147
Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164:550–63.
pubmed: 26824661
pmcid: 4754110
doi: 10.1016/j.cell.2015.12.028
Hashiya N, Jo N, Aoki M, Matsumoto K, Nakamura T, Sato Y, et al. In vivo evidence of angiogenesis induced by transcription factor Ets-1: Ets-1 is located upstream of angiogenesis cascade. Circulation. 2004;109:3035–41.
pubmed: 15173033
doi: 10.1161/01.CIR.0000130643.41587.DB
Arderiu G, Pena E, Aledo R, Espinosa S, Badimon L. Ets-1 transcription is required in tissue factor driven microvessel formation and stabilization. Angiogenesis. 2012;15:657–69.
pubmed: 22869003
doi: 10.1007/s10456-012-9293-x
Iyirhiaro GO, Zhang Y, Estey C, O’Hare MJ, Safarpour F, Parsanejad M, et al. Regulation of ischemic neuronal death by E2F4-p130 protein complexes. J Biol Chem. 2014;289:18202–13.
pubmed: 24828495
pmcid: 4140295
doi: 10.1074/jbc.M114.574145
Okumura F, Joo-Okumura A, Nakatsukasa K, Kamura T. Hypoxia-inducible factor-2alpha stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2. PLoS ONE. 2017;12:e0175593.
pubmed: 28394947
pmcid: 5386292
doi: 10.1371/journal.pone.0175593
Shao M, Ren Z, Zhang R. MYBL2 protects against H9c2 injury induced by hypoxia via AKT and NFkappaB pathways. Mol Med Rep. 2018;17:4832–8.
pubmed: 29328450
Petroulakis E, Parsyan A, Dowling RJ, LeBacquer O, Martineau Y, Bidinosti M, et al. p53-dependent translational control of senescence and transformation via 4E-BPs. Cancer Cell. 2009;16:439–46.
pubmed: 19878875
doi: 10.1016/j.ccr.2009.09.025
Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol. 2011;29:3999–4006.
pubmed: 21931021
pmcid: 3209696
doi: 10.1200/JCO.2011.35.5677
Zhao Z, Zhang KN, Wang Q, Li G, Zeng F, Zhang Y, et al. Chinese Glioma Genome Atlas (CGGA): a comprehensive resource with functional genomic data from Chinese glioma patients. Genomics Proteomics Bioinformatics. 2021;19:1–12.
pubmed: 33662628
pmcid: 8498921
doi: 10.1016/j.gpb.2020.10.005
Berchtold NC, Cribbs DH, Coleman PD, Rogers J, Head E, Kim R, et al. Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci USA. 2008;105:15605–10.
pubmed: 18832152
pmcid: 2563070
doi: 10.1073/pnas.0806883105
Pai S, Li P, Killinger B, Marshall L, Jia P, Liao J, et al. Differential methylation of enhancer at IGF2 is associated with abnormal dopamine synthesis in major psychosis. Nat Commun. 2019;10:2046.
pubmed: 31053723
pmcid: 6499808
doi: 10.1038/s41467-019-09786-7
Kobow K, Jabari S, Pieper T, Kudernatsch M, Polster T, Woermann FG, et al. Mosaic trisomy of chromosome 1q in human brain tissue associates with unilateral polymicrogyria, very early-onset focal epilepsy, and severe developmental delay. Acta Neuropathol. 2020;140:881–91.
pubmed: 32979071
pmcid: 7666281
doi: 10.1007/s00401-020-02228-5
Mack SC, Singh I, Wang X, Hirsch R, Wu Q, Villagomez R, et al. Chromatin landscapes reveal developmentally encoded transcriptional states that define human glioblastoma. J Exp Med. 2019;216:1071–90.
pubmed: 30948495
pmcid: 6504206
doi: 10.1084/jem.20190196
Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29:24–6.
pubmed: 21221095
pmcid: 3346182
doi: 10.1038/nbt.1754
Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002;1:237–46.
pubmed: 12086860
doi: 10.1016/S1535-6108(02)00043-0
Johnson TK, Schweppe RE, Septer J, Lewis RE. Phosphorylation of B-Myb regulates its transactivation potential and DNA binding. J Biol Chem. 1999;274:36741–9.
pubmed: 10593981
doi: 10.1074/jbc.274.51.36741